Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

DaVita to locate new headquarters building in a lot adjacent to Millennium Bridge

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease, announced today it will locate its new headquarters building in a lot adjacent to the Millennium Bridge, at the west end of the 16th Street Mall, across from the new Union Station development. Construction will begin in early 2011 and DaVita expects to begin occupying the building in the second half of 2012.

15 Jul 2010

Study suggests chronic kidney disease affects persons of African, Hispanic heritage at higher rate

Chronic kidney disease affects millions in North America, with persons of African heritage being at a four-fold higher risk and those of Hispanic heritage having a two-fold higher risk compared to the rest of the population. An international study carried out by Dr. Karl Skorecki, from the Technion-Israel Institute of Technology and Rambam Medical Center in Haifa, and his team points to the APOL1 gene as involved in the increased risk of kidney disease in this high-risk population. The results are to be published online in Springer's journal Human Genetics.

15 Jul 2010

Watson Laboratories files ANDA with FDA for generic Renvela for oral suspension

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market sevelamer carbonate for oral suspension, 0.8g and 2.4g per packet. Watson's sevelamer carbonate for oral suspension product is the generic version of Genzyme's Renvela for Oral Suspension.

13 Jul 2010

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Reata Pharmaceuticals, Inc. has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.

12 Jul 2010

Dysautonomia linked to CKD: Study

Individuals with a high resting heart rate and a low beat-to-beat heart rate variability have an increased risk of developing kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The findings suggest that the behavior of the autonomic nervous system may be a sentinel marker for late development of certain cases of kidney disease.

9 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Insights into complex interrelationships between heart and kidneys

Research is yielding new understanding of the interactions between the heart and the kidneys—particularly the cardiorenal syndrome, in which failure of either organ can lead to failure of the other. Recent insights into the complex interrelationships between the heart and kidneys are presented in a special symposium section of the July issue of The American Journal of Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation.

7 Jul 2010

Impax confirms challenge of patent relating to RENVELA

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.

3 Jul 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.

29 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing of the first patient with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical trial.

25 Jun 2010

Study: Low BP levels are unhealthy for CKD patients

Recent guidelines by The National Kidney Foundation Disease Outcomes Quality Initiative (NKF KDOQI)1 call for lower target blood pressure levels in patients with chronic kidney disease (CKD).

25 Jun 2010

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Moving Forward On Health Reform - This edition explores the issues relating to the implementation of the Patient Protection and Affordable Care Act of 2010, including the impact of the law on health insurance as well as state and federal governments, large employers and public opinion and opportunities for small physician practices to pool resources in order support medical homes, among others (June 2010).

19 Jun 2010

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.

16 Jun 2010

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010

Allopurinol exhibits potential benefits for CKD patients

A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a cardiovascular event or being hospitalized.

10 Jun 2010

Researchers receive funding to study care processes in patients beginning dialysis

Researchers at the University of Cincinnati and the Cincinnati Department of Veterans Affairs (VA) Medical Center have received funding to study the care processes that lead to placement of arteriovenous fistulas in patients beginning dialysis.

9 Jun 2010

Low-income African-Americans have higher risk of CKD: Research

African Americans with incomes below the poverty line have a significantly higher risk of chronic kidney disease than higher-income African-Americans or whites of any socioeconomic status, research led by scientists at Johns Hopkins and the National Institute on Aging shows. Conducted in a racially and socioeconomically diverse sample of participants from the city of Baltimore, Md., the study could help researchers eventually develop strategies to prevent CKD in vulnerable populations.

9 Jun 2010

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

DaVita to locate new headquarters building in a lot adjacent to Millennium Bridge

Study suggests chronic kidney disease affects persons of African, Hispanic heritage at higher rate

Watson Laboratories files ANDA with FDA for generic Renvela for oral suspension

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Dysautonomia linked to CKD: Study

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Insights into complex interrelationships between heart and kidneys

Impax confirms challenge of patent relating to RENVELA

European Congress of Nephrology unveils results of various clinical trials

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

ADVANCE study provides new insights into the management of SHPT in CKD patients

CorMedix announces dosing of first patient with CRMD-001 in Phase II clinical trial

Study: Low BP levels are unhealthy for CKD patients

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Newly published research examines association between CKD and CYP24

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Allopurinol exhibits potential benefits for CKD patients

Researchers receive funding to study care processes in patients beginning dialysis

Low-income African-Americans have higher risk of CKD: Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in